Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul 22;363(4):355-64.
doi: 10.1056/NEJMoa1000164.

Efficacy of gene therapy for X-linked severe combined immunodeficiency

Salima Hacein-Bey-Abina  1 , Julia Hauer, Annick Lim, Capucine Picard, Gary P Wang, Charles C Berry, Chantal Martinache, Frédéric Rieux-Laucat, Sylvain Latour, Bernd H Belohradsky, Lily Leiva, Ricardo Sorensen, Marianne Debré, Jean Laurent Casanova, Stephane Blanche, Anne Durandy, Frederic D Bushman, Alain Fischer, Marina Cavazzana-Calvo
Affiliations

Efficacy of gene therapy for X-linked severe combined immunodeficiency

Salima Hacein-Bey-Abina et al. N Engl J Med. .

Abstract

Background: The outcomes of gene therapy to correct congenital immunodeficiencies are unknown. We reviewed long-term outcomes after gene therapy in nine patients with X-linked severe combined immunodeficiency (SCID-X1), which is characterized by the absence of the cytokine receptor common gamma chain.

Methods: The nine patients, who lacked an HLA-identical donor, underwent ex vivo retrovirus-mediated transfer of gamma chain to autologous CD34+ bone marrow cells between 1999 and 2002. We assessed clinical events and immune function on long-term follow-up.

Results: Eight patients were alive after a median follow-up period of 9 years (range, 8 to 11). Gene therapy was initially successful at correcting immune dysfunction in eight of the nine patients. However, acute leukemia developed in four patients, and one died. Transduced T cells were detected for up to 10.7 years after gene therapy. Seven patients, including the three survivors of leukemia, had sustained immune reconstitution; three patients required immunoglobulin-replacement therapy. Sustained thymopoiesis was established by the persistent presence of naive T cells, even after chemotherapy in three patients. The T-cell-receptor repertoire was diverse in all patients. Transduced B cells were not detected. Correction of the immunodeficiency improved the patients' health.

Conclusions: After nearly 10 years of follow-up, gene therapy was shown to have corrected the immunodeficiency associated with SCID-X1. Gene therapy may be an option for patients who do not have an HLA-identical donor for hematopoietic stem-cell transplantation and for whom the risks are deemed acceptable. This treatment is associated with a risk of acute leukemia. (Funded by INSERM and others.)

PubMed Disclaimer

Figures

Figure 1
Figure 1. Vector Copy Numbers and T-Cell Subgroups after Gene Therapy
Patients were categorized into two groups: those in whom severe adverse events did not develop (Patients 1, 2, 6, and 8; left side of each panel) and those in whom severe adverse events did develop (Patients 4, 5, 7, and 10; right side of each panel). Panel A shows the vector copy number in peripheral-blood mononuclear cells over time. In Patient 10, blast cells contained two copies, as previously reported. Panel B shows short-term and Panel C shows long-term T-cell reconstitution as evidenced by absolute CD3+ lymphocyte counts in whole blood, measured with the use of flow cytometry. Panel D shows the change over time in absolute numbers of CD4+ T cells, and Panel E shows the change over time in absolute numbers of CD45RA+CD4+–naive T lymphocytes in whole blood, as measured with the use of flow cytometry. Panel F shows the change over time in the number of T-cell–receptor excision circles (TRECs) in peripheral-blood mononuclear cells (PBMCs). Panel G shows the change over time in the absolute numbers of CD3+CD8+ T cells in whole blood, as measured with the use of flow cytometry. In Panels B, C, D, E, F, and G, the shaded areas indicate reference values for age-matched controls. In Panels A, C, D, E, F, and G, the arrows indicate the occurrence of leukemia and the duration of chemotherapy.
Figure 2
Figure 2. Serum Immunoglobulin Levels and Memory B-Cell Counts after Gene Therapy
The changes over time in levels of serum IgG (Panel A), IgA (Panel B), and IgM (Panel C) in Patients 1, 2, 6, and 8 (left side of each panel) and Patients 4, 5, 7, and 10 (right side of each panel) are shown. Data on IgG levels in Patients 6, 7, and 10 (who received immunoglobulin-replacement therapy) are not shown. Panel D shows the change over time in the proportion of CD19+CD27+ memory B cells as measured with the use of flow cytometry in Patients 1, 2, 6, 7, and 8. In all panels, arrows indicate the occurrence of leukemia and the duration of chemotherapy. The shaded areas indicate reference values for age-matched controls.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sugamura K, Asao H, Kondo M, et al. The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Annu Rev Immunol. 1996;14:179–205. - PubMed
    1. Leonard WJ. Cytokines and immunodeficiency diseases. Nat Rev Immunol. 2001;1:200–8. - PubMed
    1. Noguchi M, Yi H, Rosenblatt HM, et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 1993;73:147–57. - PubMed
    1. Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 1999;340:508–16. - PubMed
    1. Antoine C, Müller S, Cant A, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99. Lancet. 2003;361:553–60. - PubMed

Publication types

MeSH terms